A randomized, placebo-controlled, phase II, presurgical biomarker trial of Celecoxib versus exemestane in postmenopausal breast cancer patients

Cancer Prevention Research

Volumn 9, Issue 5, 2016, Pages 349-356

  Aristarco, Valentina ^a   Serrano, Davide ^a   Gandini, Sara ^a   Johansson, Harriet ^a   Macis, Debora ^a   Guerrieri Gonzaga, Aliana ^a   Lazzeroni, Matteo ^a   Feroce, Irene ^a   Pruneri, Giancarlo ^a   Pagani, Gianmatteo ^a   Toesca, Antonio ^a   Caldarella, Pietro ^a   DeCensi, Andrea ^b,c   Bonanni, Bernardo ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b GALLIERA HOSPITAL   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BIOLOGICAL MARKER; CELECOXIB; ESTROGEN RECEPTOR; EXEMESTANE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KI 67 ANTIGEN; PLACEBO; PROGESTERONE RECEPTOR; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; AGED; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HOT FLUSH; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MUSCULOSKELETAL PAIN; NIGHT SWEAT; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; BIOSYNTHESIS; BREAST NEOPLASMS; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED;

AGED; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELECOXIB; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; POSTMENOPAUSE;

EID: 84969922808     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-15-0311     Document Type: Article

References (57)

1. Yerushalmi R, Woods R, Ravdin PM, HayesMM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010;11:174-83.
2. Kalinsky K, Hershman DL. Cracking open window of opportunity trials. J Clin Oncol 2012;30:2573-5.
3. Decensi A, Guerrieri-Gonzaga A, Gandini S, Serrano D, Cazzaniga M, Mora S, et al. Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with Er-positive breast cancer. Ann Oncol 2010;22:582-7.
4. Decensi A, Puntoni M, Pruneri G, Guerrieri-Gonzaga A, Lazzeroni M, Serrano D, et al. Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. Cancer Prev Res 2011;4:1181-9.
5. Decensi A, Guerrieri-Gonzaga A, Pruneri G, Puntoni M, Cazzaniga M, Vingiani A, et al. Metformin decreases Ki67 in HER2+ve ductal carcinoma in situ in a window of opportunity trial [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2014 Dec 9-13 ; San Antonio, TX. Philadelphia (PA): AACR. Abstract nr P5-12-02.
6. Lonning PE. Exemestane: a review of its clinical efficacy and safety. Breast 2001;10:198-208.
7. Van AK, Neven P, Lintermans A, Wildiers H, Paridaens R. Aromatase inhibitors in the breast cancer clinic: focus on exemestane. Endocr Relat Cancer 2014;21:R31-49.
8. Goss PE, Ingle JN, Aĺ s-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364:2381-91.
9. Lonning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005;23:5126-37.
10. Harris RE, Casto BC, Harris ZM. Cyclooxygenase-2 and the inflammogenesis of breast cancer. World J Clin Oncol 2014;5:677-92.
11. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, et al. Cox-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000;89:2637-45.
12. Barnes NL, Warnberg F, Farnie G, White D, Jiang W, Anderson E, et al. Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. Br J Cancer 2007;96:575-82.
13. Diaz-Cruz ES, Shapiro CL, Brueggemeier RW. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 2005;90:2563-70.
14. Moorman PG, Grubber JM, Millikan RC, Newman B. Association between non-steroidal anti-inflammatory drugs (NSAIDS) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 2003; 14:915-22.
15. Bowers LW, Maximo IX, Brenner AJ, Beeram M, Hursting SD, Price RS, et al. NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactions. Cancer Res 2014; 74:4446-57.
16. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol 2010; 28:1467-72.
17. Mukherjee D. Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor. Thromb Haemost 2006;96:407-12.
18. Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'orto P, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrineresponsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008; 26:5569-75.
19. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736-47.
20. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, et al. Shortterm changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005;11:951s-8s.
21. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'hern R, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007;99:167-70.
22. Tubiana-Hulin M, Becette V, Bieche I, Mauriac L, Romieu G, Bibeau F, et al. Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial. Anticancer Res 2007;27:2689-96.
23. DecensiA, RobertsonC, Viale G, Pigatto F, JohanssonH, Kisanga ER, et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 2003;95:779-90.
24. EllisMJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol 2011;29:2342-9.
25. Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and Her-2 in breast cancer-a study from the impact trialists. J Clin Oncol 2005;23:2477-92.
26. Ellis MJ, Ma C. Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat 2007;105 Suppl 1:33-43.
27. Bundred NJ, Cramer A, Morris J, Renshaw L, Cheung KL, Flint P, et al. Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial. Clin Cancer Res 2010; 16:1605-12.
28. Mlineritsch B, Tausch C, Singer C, Luschin-Ebengreuth G, Jakesz R, Ploner F, et al. Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17). Breast Cancer Res Treat 2008;112:203-13.
29. Toi M, Saji S, Masuda N, Kuroi K, Sato N, Takei H, et al. Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition. Cancer Sci 2011; 102:858-65.
30. Polley MY, Leung SC, Gao D, Mastropasqua MG, Zabaglo LA, Bartlett JM, et al. An international study to increase concordance in Ki67 scoring. Mod Pathol 2015;28:778-86
31. Goss PE, Richardson H, Chlebowski R, Johnston D, Sarto GE, Maunsell E, et al. National Cancer Institute Of Canada Clinical Trials Group Map.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women. Clin Breast Cancer 2007;7:895-900.
32. Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebocontrolled trial. Lancet 2014;383:1041-8.
33. Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, Decensi A, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 2013; 381:1827-34.
34. Gallicchio L, Macdonald R, Wood B, Rushovich E, Helzlsouer KJ. Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy. Breast Cancer Res Treat 2011; 130:569-77.
35. Rossi E, Morabito A, Di Rella F, Esposito G, Gravina A, Labonia V, et al. Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol 2009;27:3192-7.
36. Ingle JN, Buzdar AU, Schaid DJ, Goetz MP, Batzler A, Robson ME, et al. Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res 2010;70:3278-86.
37. Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, et al. Serum sex steroids in premenopausal women and breast cancer risk within the european prospective investigation into Cancer And Nutrition (EPIC). J Natl Cancer Inst 2005;97:755-65.
38. Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE. Endogenous steroid hormone concentrations and risk of breast cancer: does the association vary by a woman's predicted breast cancer risk? J Clin Oncol 2006;24:1823-30.
39. Micheli A, Meneghini E, Secreto G, Berrino F, Venturelli E, Cavalleri A, et al. Plasma testosterone and prognosis of postmenopausal breast cancer patients. J Clin Oncol 2007;25:2685-90.
40. Rock CL, Flatt SW, Laughlin GA, Gold EB, Thomson CA, Natarajan L, et al. Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer. Cancer Epidemiol Biomarkers Prev 2008; 17:614-20.
41. Emond JA, Patterson RE, Natarajan L, Laughlin GA, Gold EB, Pierce JP. Sex hormone concentrations and the risk of breast cancer recurrence in postmenopausal women without hot flashes. Cancer Epidemiol Biomarkers Prev 2011;20:939-45.
42. Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A, Afanasyeva Y, Kato I, et al. Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. Br J Cancer 2004;90:153-9.
43. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9: 45-53.
44. Cuzick J. IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther 2008;8:1377-85.
45. Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, et al. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised ontrolled trial. Lancet. 2015 Dec 11. [Epub ahead of print].
46. Shapiro Cl. Aromatase inhibitors and bone loss: risks in perspective. J Clin Oncol 2005;23:4847-9.
47. Mccloskey EV, Hannon RA, Lakner G, Fraser WD, Clack G, Miyamoto A, et al. Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer 2007;43:2523-31.
48. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007;8:119-27.
49. Chow LW, Yip AY, Chu WP, Loo WT, Toi M. Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial. J Steroid Biochem Mol Biol 2011;125:112-9.
50. Bundred NJ, Cramer A, Morris J, Renshaw L, Cheung KL, Flint P, et al. Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial. Clin Cancer Res 2010; 16:1605-12.
51. Generali D, Buffa FM, Deb S, CummingsM, Reid LE, TaylorM, et al. Cox-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment. Br J Cancer 2014;111:46-54.
52. Martin LA, DaviesGL, Weigel MT, Betambeau N, Hills MJ, Salter J, et al. Presurgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer. Breast Cancer Res Treat 2010;123:829-36.
53. Brand~ao RD, Veeck J, Van de Vijver KK, Lindsey P, de Vries B, van Elssen CH, et al. A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. Breast Cancer Res 2013;15:R29.
54. Maunsell E, Goss PE, Chlebowski RT, Ingle JN, Aĺs-Martinez JE, Sarto GE, et al. Quality of life in Map.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol 2014;32:1427-36.
55. Polley MY, Leung SC, Mcshane LM, Gao D, Hugh JC, Mastropasqua MG, et al. An international Ki67 reproducibility study. J Natl Cancer Inst 2013;105:1897-906.
56. Waters EA, Mcneel TS, Stevens WM, Freedman AN. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat 2012;134:875-80.
57. Decensi A, Thorat MA, Bonanni B, Smith SG, Cuzick J. Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake. Ecancermedicalscience 2015;9:595.